



## **Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference**

February 10, 2022

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the SVB Leerink 11<sup>th</sup> Annual Global Healthcare Conference on Thursday, February 17, 2022 at 11:20 a.m. ET.

A live webcast will be available in the investor section of the company's website at [www.designtx.com](http://www.designtx.com). The webcast will be archived for 30 days following the presentation.

### **About Design Therapeutics**

Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company's GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. Design's lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. For more information, please visit [designtx.com](http://designtx.com).

### **Contact:**

Investors:

Chelcie Lister

THRUST Strategic Communications

[chelcie@thrustsc.com](mailto:chelcie@thrustsc.com)